Target Group Inc.

OTC: CBDY · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Hamilton, ONCIK 0001586554Reports USD

#720 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

46D

FH 40DQ 62GM 31SS 42

v0.1 · 65/100 weight · provisional

↑ filing timeliness, return on assets · ↓ balance-sheet leverage, revenue growth (YoY)

Methodology →

Revenue TTM

$3.4M

Rev growth YoY (TTM)

-44.4%

Net income (FY)

-$1.4M

Employees

Market cap

$740.4k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$3.9M$3.9M2025

Net income-$1.4M-$1.4M2025

Total assets$6.2M$6.2M2025

Liabilities$14.2M$14.2M2025

Equity-$8.1M-$8.1M2025

Revenue trend

FY2019 – FY2025 · USD

$263

FY19

$30.0k

FY20

FY22

FY23

$3.7M

FY23

$6.6M

FY24

$3.9M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Target Group Inc. booked $3.9M in FY2025 revenue, contracting 41% year over year — slower than 80% of Healthcare companies we track, at a -35.0% net margin.

Peers · Healthcare

BioQuest Corp.——Emmaus Life Sciences, Inc.40D Aspire Biopharma Holdings, Inc.17D Kaya Holdings, Inc.——

Key facts

CEOAnthony Carlo Zarcone

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersHamilton, ON

ExchangeOTC: CBDY

Employees41

IPO date2015-12-28

Latest filings

10-Q2026-05-15 10-K2026-03-31 10-Q2025-11-07 8-K2025-08-18 10-Q2025-08-12 10-Q2025-05-09 10-K2025-03-27 10-Q2024-11-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.